Flurbiprofen-d₃is intended for use as an internal standard for the quantification of flurbiprofen by GC- or LC-MS. Flurbiprofen is a non-selective COX inhibitor (IC₅₀s = 0.04 and 0.51 μM for COX-1 and COX-2, respectively).¹In vivo, flurbiprofen (0.3-4.8 mg/kg, p.o.) reduces carrageenan-induced hind paw edema and yeast-induced fever in rats.²Flurbiprofen reduces plasma fibrinogen levels and arthritic score in a rat model of adjuvant-induced arthritis. It also reduces tumor weight and prostaglandin production and increases survival in a WHT-NC mouse xenograft model when administered at a dose of 5 mg/kg.³Formulations containing flurbiprofen have been used to manage pain and inflammation associated with arthritis.

1.Barnett, J., Chow, J., Ives, D., et al.Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus systemBiochim Biophys. Acta.1209(1)130-139(1994) 2.Glenn, E.M., Rohloff, N., Bowman, B.J., et al.The pharmacology of 2-(2-fluoro-4-biphenylyl)propionic acid (flurbiprofen). A potent non-steroidal anti-inflammatory drugAgents Actions3(4)210-216(1973) 3.Bennett, A., Houghton, J., Leaper, D.J., et al.Tumour growth and response to treatment: Beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen [proceedings]Br. J. Pharmacol.63(2)356P-357P(1978)